Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avinger

Vinco Ventures

BitNile Holdings

Short squeeze penny stocks to watch right now. The post Top Penny Stocks To Buy Right Now?

Top Penny Stocks To Buy Right Now? 4 Short Squeeze Stocks To Watch

If it can become the go-to collaborator for its specialty, yes.

Is Ginkgo Bioworks a Warren Buffett Stock?

Presentation and Q&A session scheduled for post-market on Monday, March 28, 2022 BOSTON , March 17, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2021, on Monday, March 28, 2022, beginning at 4:30 p.m. ET. The presentation details and webcast registration link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com and a replay will be made available.

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2021 Results Presentation and Date for Annual Meeting of Shareholders

BOSTON , March 15, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in a fireside chat at Jefferies Virtual Synthetic Biology Week, on March 22, 2022, at 10:00 a.m. Eastern Time.

Ginkgo Bioworks Announces Participation in Jefferies Virtual Synthetic Biology Week

BOSTON and BASEL, Switzerland , March 14, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire FGen AG ("FGen"), a Swiss company specializing in strain development and optimization. FGen has developed an ultra-high-throughput (uHT) screening platform built on nanoliter reactor technology.

Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform

The companies seek to leverage cell programming to produce betalain pigments across the full yellow-to-purple spectrum YOKNEAM ILLIT, Israel, Feb. 28, 2022 /PRNewswire/ -- Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit.

Phytolon and Ginkgo Bioworks Collaborate to Take Biological Production of Vibrant Food Colors to the Next Level

Riot Blockchain

From biotech to blockchain, there is no shortage of growth opportunities here.

2 Growth Stocks That Wall Street Thinks Can Double in Value

BOSTON , Feb. 24, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in the following upcoming conferences: Truist Securities AI Symposium - Biotech & Tools on Tuesday, March 1, 2022, at 9:00 a.m. ET Cowen 42nd Annual Health Care Conference  Fireside chat on Tuesday, March 8, 2022, at 2:10 p.m.

Ginkgo Bioworks Announces Participation in Upcoming Conferences

Ginkgo Bioworks is still a story stock and one that's expensive to buy into.

Is This SPAC a Buy After Falling More Than 50%?

CrowdStrike

Freshworks

Lucid Group

Vail Resorts

Playtika Holding

Twitter

With sentiment souring over inflation and other concerns, contrarians may have an opportunity to bank on certain stocks to buy like these. The post 7 Stocks to Buy After Sentiment Slipped to Lows appeared first on InvestorPlace.

7 Stocks to Buy After Sentiment Slipped to Lows

San Diego, California--(Newsfile Corp. - February 1, 2022) - Johnson Fistel, LLP is investigating potential claims on behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) against certain of its officers and directors.Recently, a class action complaint was filed against Ginkgo. According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) the Company's failure to derive real revenue from third-party customers left it almost completely...

Did You Acquire (DNA) Before May 11, 2021? Should Management be Held Accountable for Investors Losses?

Grab Holdings Ltd

Infinera

Kinross Gold

Vroom

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Buy-Rated Stocks Trading Under $10 With Giant Upside Potential

Root

Seanergy Maritime Hlds

Can these penny stocks push up next month? The post Best Penny Stocks to Buy Next Month?

Best Penny Stocks to Buy Next Month? Check These 3 Out

Ginkgo Bioworks Holdings Inc DNA is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities. The Ginkgo Bioworks Analyst: Derik de Bruin initiated coverage of Ginkgo Bioworks with a Buy rating and $8 price target.

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Acquisition to enable Ginkgo to bolster its growing biosecurity platform and provide expanded COVID-19 testing options to communities in Massachusetts and beyond BOSTON, Jan. 19, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the acquisition of Project Beacon COVID-19 LLC (Project Beacon), a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing. Under the terms of the deal, Ginkgo acquired Project Beacon's assets and will assume responsibility for Project Beacon's ongoing operations, providing COVID-19 monitoring tools to communities in Massachusetts and other areas.

Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed

BOSTON, Jan. 19, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the acquisition of Project Beacon COVID-19 LLC (Project Beacon), a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing. Under the terms of the deal, Ginkgo acquired Project Beacon's assets and will assume responsibility for Project Beacon's ongoing operations, providing COVID-19 monitoring tools to communities in Massachusetts and other areas.

Ginkgo Bioworks Announces Acquisition of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC

NEW YORK , Jan. 17, 2022 /PRNewswire/ --  Pomerantz LLP is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ginkgo Bioworks Holdings, Inc. - DNA

Soaring Eagle Acquisition Corp

New York, New York--(Newsfile Corp. - January 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (NYSE: DNA) (NASDAQ: SRNG) between May 11, 2021 and October 5, 2021, both dates inclusive (the "Class Period"), of the important January 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased Ginkgo securities during the Class Period you may be...

DNA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action Commenced by the Firm - DNA, SR

New York, New York--(Newsfile Corp. - January 17, 2022) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). Shareholders who purchased shares of DNA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ginkgo-bioworks-holdings-inc-loss-submission-form/?id=22122&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022 - (DNA)

New York, New York--(Newsfile Corp. - January 17, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo Bioworks") between May 11, 2021 and October 5, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/ginkgo-bioworks-holdings-inc-loss-submission-form?prid=22120&wire=5

DNA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Ginkgo Bioworks Holdings, Inc.

New York, New York--(Newsfile Corp. - January 16, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) alleging that the Company violated federal securities laws.Class Period: May 11, 2021 to October 5, 2021Lead Plaintiff Deadline: January 18, 2022No obligation or cost to you.Learn more about your recoverable losses in DNA:https://www.kleinstocklaw.com/pslra-1/ginkgo-bioworks-holdings-inc-loss-submission-form?id=22106&from=5

DNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 18, 2022 in the Class Action Filed on Behalf of Ginkgo Bioworks Holdings, Inc. Limited Shareholders

Radnor, Pennsylvania--(Newsfile Corp. - January 16, 2022) -  The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE: DNA) f/k/a Soaring Eagle Acquisition Corp. (NASDAQ: SRNG). The action charges Ginkgo with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Ginkgo's materially...

DNA DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit

New York, New York--(Newsfile Corp. - January 16, 2022) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks") (NYSE: DNA) between May 11, 2021 and October 5, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022 - DNA

New York, New York--(Newsfile Corp. - January 14, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (NYSE: DNA) (NASDAQ: SRNG) between May 11, 2021 and October 5, 2021, both dates inclusive (the "Class Period"), of the important January 18, 2022 lead plaintiff deadline.SO WHAT: If you purchased Ginkgo securities during the Class Period you may be...

DNA Final Deadline: Rosen, Globally Recognized Investor Counsel, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors with Losses to Secure Counsel Before Important January 18 Deadline in Securities Class Action Commen

Los Angeles, California--(Newsfile Corp. - January 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. ("Ginkgo" or "the Company") (NYSE: DNA) (NASDAQ: SRNG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Deadline Tuesday Notice: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for Ginkgo Bioworks Holdings Stock (DNA)